JP2014530231A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530231A5 JP2014530231A5 JP2014535166A JP2014535166A JP2014530231A5 JP 2014530231 A5 JP2014530231 A5 JP 2014530231A5 JP 2014535166 A JP2014535166 A JP 2014535166A JP 2014535166 A JP2014535166 A JP 2014535166A JP 2014530231 A5 JP2014530231 A5 JP 2014530231A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- container
- mdi
- metered dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1117621.1 | 2011-10-12 | ||
| GB201117621A GB201117621D0 (en) | 2011-10-12 | 2011-10-12 | Compositions |
| PCT/GB2012/052542 WO2013054135A1 (en) | 2011-10-12 | 2012-10-12 | Compositions comprising salbutamol sulphate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530231A JP2014530231A (ja) | 2014-11-17 |
| JP2014530231A5 true JP2014530231A5 (enExample) | 2014-12-25 |
| JP5818290B2 JP5818290B2 (ja) | 2015-11-18 |
Family
ID=45091933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535166A Active JP5818290B2 (ja) | 2011-10-12 | 2012-10-12 | 硫酸サルブタモールを含有する組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9114164B2 (enExample) |
| EP (1) | EP2766005B1 (enExample) |
| JP (1) | JP5818290B2 (enExample) |
| CN (1) | CN103857388B (enExample) |
| AU (1) | AU2012322453B2 (enExample) |
| BR (1) | BR112014008609B1 (enExample) |
| CA (1) | CA2851764C (enExample) |
| ES (1) | ES2556585T3 (enExample) |
| GB (1) | GB201117621D0 (enExample) |
| MX (1) | MX336225B (enExample) |
| WO (1) | WO2013054135A1 (enExample) |
| ZA (1) | ZA201402234B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201306984D0 (en) | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
| CN107206000A (zh) | 2014-12-22 | 2017-09-26 | 阿鲁兹特拉生物有限公司 | 预防和治疗血小板增多的癌症患者中的转移性疾病 |
| CA3007050C (en) * | 2015-12-04 | 2020-12-08 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition comprising a formoterol compound |
| GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| EP3515425B1 (en) | 2016-09-19 | 2021-06-09 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition comprising salmeterol |
| CN109715160A (zh) | 2016-09-19 | 2019-05-03 | 墨西哥氟石股份公司 | 药物组合物 |
| EP3922240B1 (en) * | 2016-09-19 | 2023-06-21 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition comprising tiotropium bromide |
| ES2968453T3 (es) | 2016-09-19 | 2024-05-09 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende glicopirrolato |
| GB2573297A (en) * | 2018-04-30 | 2019-11-06 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| FR3130554B1 (fr) | 2021-12-20 | 2024-10-18 | Aptar France Sas | Composition pharmaceutique comprenant du salbutamol |
| FR3137830A1 (fr) | 2022-07-13 | 2024-01-19 | Aptar France Sas | Composition pharmaceutique comprenant du salbutamol |
| US12383516B1 (en) | 2025-01-06 | 2025-08-12 | Amphastar Pharmaceuticals, Inc. | Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| US5439670A (en) | 1989-11-28 | 1995-08-08 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| IE67185B1 (en) | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
| DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| JP3908269B2 (ja) * | 1991-12-18 | 2007-04-25 | スリーエム カンパニー | 懸濁エアゾール製剤 |
| US7105152B1 (en) * | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
| CZ288146B6 (en) | 1994-12-22 | 2001-05-16 | Astra Ab | Pharmaceutical aerosol preparation, process of its preparation and use |
| HU219899B (hu) | 1995-04-14 | 2001-09-28 | Glaxo Wellcome Inc. | Inhalálóberendezés flutikaszon-propionát adagolására mért dózisban |
| CZ300758B6 (cs) | 1997-09-29 | 2009-08-05 | Nektar Therapeutics | Práškovitý prípravek obsahující perforované mikrostruktury |
| US6103266A (en) | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
| US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| CA2338680C (en) | 1998-08-04 | 2008-10-14 | Jago Research Ag | Medicinal aerosol formulations |
| GB2392164B (en) | 1999-09-11 | 2004-04-07 | Glaxo Group Ltd | Pharmaceutical formulation of fluticasone propionate |
| US6432415B1 (en) | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
| CN1144582C (zh) | 2000-11-28 | 2004-04-07 | 中国药科大学 | 治疗呼吸系统疾病的无氟里昂药用气雾剂 |
| CN1216600C (zh) | 2002-04-24 | 2005-08-31 | 信谊药厂 | 盐酸左旋沙丁胺醇气雾剂及制备工艺 |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| GB0323685D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| US20060018840A1 (en) | 2004-06-28 | 2006-01-26 | Nektar Therapeutics | Aerosolizable formulation comprising nicotine |
| WO2007020204A2 (en) | 2005-08-12 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate |
| GB0915106D0 (en) | 2009-08-28 | 2009-10-07 | Glaxo Group Ltd | Process |
-
2011
- 2011-10-12 GB GB201117621A patent/GB201117621D0/en not_active Ceased
-
2012
- 2012-10-12 CN CN201280049813.9A patent/CN103857388B/zh active Active
- 2012-10-12 ES ES12787053.3T patent/ES2556585T3/es active Active
- 2012-10-12 MX MX2014004364A patent/MX336225B/es unknown
- 2012-10-12 JP JP2014535166A patent/JP5818290B2/ja active Active
- 2012-10-12 AU AU2012322453A patent/AU2012322453B2/en active Active
- 2012-10-12 CA CA2851764A patent/CA2851764C/en active Active
- 2012-10-12 WO PCT/GB2012/052542 patent/WO2013054135A1/en not_active Ceased
- 2012-10-12 BR BR112014008609-5A patent/BR112014008609B1/pt active IP Right Grant
- 2012-10-12 US US14/351,001 patent/US9114164B2/en active Active
- 2012-10-12 EP EP12787053.3A patent/EP2766005B1/en active Active
-
2014
- 2014-03-26 ZA ZA2014/02234A patent/ZA201402234B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530231A5 (enExample) | ||
| JP2014528470A5 (enExample) | ||
| JP2007106777A5 (enExample) | ||
| Zhou et al. | Emerging inhalation aerosol devices and strategies: where are we headed? | |
| JP2010132695A5 (enExample) | ||
| HRP20140582T4 (hr) | Kombinacijska terapija za copd | |
| MX2014004279A (es) | Composiciones que comprenden sulfato de salbutamol. | |
| MX336225B (es) | Composiciones que comprenden sulfato de salbutamol. | |
| TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
| HK1203149A1 (en) | Novel dosage form and formulation of abediterol | |
| JP2013544781A5 (enExample) | ||
| GB201118188D0 (en) | Manufacture of medicinal aerosol canisters | |
| WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
| WO2009112274A3 (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| PH12014502746A1 (en) | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same | |
| HRP20140550T1 (hr) | Aerosolna formulacija za copd | |
| CN111936124A (zh) | 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用 | |
| MX370890B (es) | Composición que comprende sulfato de salbutamol. | |
| NZ599900A (en) | Pharmaceutical suspension aerosol formulations for use in metered dose inhalers | |
| WO2011061498A3 (en) | Inhalation solutions | |
| CY1117596T1 (el) | Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης | |
| MY187442A (en) | A pharmaceutical composition containing budesonide and formoterol | |
| MX2014001940A (es) | Producto farmaceutico de aerosol para administracion por inhalacion oral o nasal. | |
| WO2011049540A3 (en) | The pharmaceutical composition in dry powder form for inhalation | |
| PH12014500440A1 (en) | Method for preparing metered dose sprayed inhaler for treating respiratory disease |